The Critical Path Institute (C-Path) is poised to convene its landmark 2026 Global Impact Conference (CGIC) this September in Washington, D.C., a pivotal event that will gather some of the most influential voices across the global drug development ecosystem. Over the course of September 15-16, followed by a specialized session on September 17, the conference aims to tackle critical challenges surrounding the transformation of evidence generation—a fundamental cornerstone of how therapies are developed, evaluated, and ultimately delivered to patients around the world.
At the forefront of this conference is the pressing need to fundamentally rethink how evidence of efficacy and safety for new treatments is generated, interpreted, and leveraged in regulatory decision-making. This reflects a growing recognition that traditional paradigms are no longer sufficient for addressing the complexity and pace of today’s biomedical innovations. CGIC 2026 builds on the multi-year trajectory of previous conferences, which explored novel evidence sources in 2024 and focused on modernizing evidence generation in 2025, signaling a deliberate evolution toward a future-oriented framework for drug development sciences.
The opening keynote, delivered by Dr. Michael Davis, acting director of the FDA’s Center for Drug Evaluation and Research, is expected to underscore the regulatory perspective on these emerging challenges. His address will be complemented by a keynote on the following day from Dr. Janet Woodcock, former principal deputy commissioner of the FDA, whose insights on innovation in drug evaluation and regulatory science are highly anticipated by the community.
C-Path’s Chief Executive Officer Klaus Romero emphasizes the urgency of catalyzing a new paradigm that accelerates patient access to transformative therapies while maintaining rigorous standards of safety and efficacy. Romero’s remarks highlight how CGIC serves as a dynamic platform where regulatory authorities, industry leaders, academic researchers, patient advocates, and individuals with lived experience converge to co-create sustainable solutions to persistent drug development bottlenecks.
The breadth of the conference agenda reflects the complexity of current evidence generation demands, encompassing artificial intelligence (AI) methodologies, real-world data integration, advanced digital health technologies, and biomarkers development. Each of these technological and methodological advances holds promise for reshaping clinical trials and post-market surveillance by enhancing data accuracy, patient-centricity, and predictive power.
Notably, CGIC 2026 will devote significant attention to digital endpoints, which represent an innovative class of biomarkers derived through wearable sensors and mobile devices that capture health outcomes with unprecedented granularity and ecological validity. Discussions will extend to biological staging as a clinical trial tool, enabling stratified approaches that match therapeutic interventions to disease progression markers—thereby refining both trial design and therapeutic targeting.
The role of neuroimaging biomarkers in early-stage drug development is another critical focus area. These biomarkers provide objective, quantifiable signals of neurological disease activity and treatment response, which is especially valuable in the context of neurodegenerative disorders where clinical endpoints can be elusive or slow to manifest.
Post-approval evidence generation is addressed with an emphasis on real-world evidence (RWE), which complements randomized controlled trials by offering insights into a therapy’s performance in heterogeneous patient populations under routine clinical care. The conference will explore how regulatory frameworks can be adapted to better incorporate RWE, thereby supporting dynamic benefit-risk assessments throughout a drug’s lifecycle.
A particularly transformative initiative featured at CGIC 2026 is “One to Millions,” aimed at revolutionizing the development, evaluation, and reimbursement pathways for individualized therapies. This initiative confronts the scalability challenges of personalized medicine—moving from bespoke treatments addressing single patients to scalable solutions capable of delivering therapies to much larger populations without sacrificing regulatory rigor or economic viability.
Trust and transparency in data sharing will be a recurring theme, recognizing that collaborative data ecosystems are essential for advancing personalized medicine. Ethical, privacy, and technical considerations surrounding data interoperability and patient confidentiality will be critically examined to foster more robust data sharing infrastructures.
The conference will also integrate perspectives from lived experiences, ensuring that patient voices directly inform and shape regulatory science and drug development practices. This commitment to patient-centricity aligns with a broader paradigm shift recognizing patients as active partners in research, development, and regulatory processes, rather than passive subjects.
Moreover, experts will address the regulatory nuances across diverse therapeutic domains, emphasizing the heterogeneity of evidence generation needs and the necessity for tailored regulatory pathways that accommodate innovative modalities, including gene therapies and novel drug delivery technologies.
Another key scientific discussion thread pertains to New Approach Methodologies (NAMs), which encompass non-animal testing methods leveraging in vitro systems, computational modeling, and systems biology approaches to predict drug effects. NAMs promise to accelerate drug development timelines while enhancing human relevance and reducing reliance on traditional animal testing.
CGIC 2026 also foregrounds opportunities for multidisciplinary networking, enabling biopharmaceutical innovators, regulators, academia, patient advocates, and payors to forge new partnerships. This cross-sector engagement is vital for translating scientific advances into tangible public health benefits through streamlined development pathways, innovative reimbursement models, and regulatory acceptance.
In sum, the 2026 Global Impact Conference by the Critical Path Institute represents a seminal convergence of scientific rigor, regulatory innovation, and patient-centered advocacy. Its emphasis on transforming evidence generation paradigms stands to catalyze a new era in drug development—one marked by agility, inclusivity, and precision. By fostering collaborative dialogue and advancing methodological breakthroughs, CGIC 2026 is poised to accelerate the translation of cutting-edge science into therapies that reach patients faster and with greater reliability than ever before.
Subject of Research: Innovations and paradigm shifts in evidence generation for drug development, with focus on individualized therapies and regulatory science.
Article Title: Transforming Evidence Generation: Inside the Critical Path Institute’s 2026 Global Impact Conference
News Publication Date: June 9, 2026
Web References:
https://bit.ly/CGIC2026
https://c-path.org/program/one-to-millions/
https://c-path.org/
Keywords:
drug development, evidence generation, regulatory science, personalized medicine, real-world data, biomarkers, neuroimaging, digital endpoints, artificial intelligence, New Approach Methodologies, patient advocacy, clinical trials.
Tags: advanced drug safety assessmentbiomedical innovation challengesCritical Path Institute 2026 conferenceevidence generation in drug developmentFDA drug evaluation insightsfuture of drug development sciencesglobal drug development leadersglobal impact in pharmaceutical researchinnovative therapy delivery methodsmodernizing clinical evidence frameworksnew treatment efficacy evaluationtransforming regulatory decision-making
